Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Spero Therapeutics Plummets 15% on FDA's CRL for Tebipenem HBr New Drug Application

Published 06/28/2022, 04:30 AM
Updated 06/28/2022, 04:30 AM
© Reuters.

By Davit Kirakosyan

Spero Therapeutics , Inc. (Nasdaq: NASDAQ:SPRO) shares plunged around 15% after-hours following the company’s announcement, according to which the U.S. Food and Drug Administration (FDA) had completed its review of the New Drug Application (NDA) for tebipenem HBr oral tablets for the treatment of adult patients with complicated urinary tract infection (cUTI) and determined that the NDA could not be approved in its present form.

The agency concluded that the company’s Phase 3 cUTI study of tebipenem HBr (ADAPT-PO) was insufficient to support approval and that additional clinical study would be required, setting a Prescription Drug User Fee Act (PDUFA) target action date of June 27.

The company intends to promptly request a Type A meeting with the FDA in order to gain further insights as to the pathway forward towards a potential regulatory approval for tebipenem HBr.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.